Review of Apremilast Combination Therapies in the Treatment of Moderate to Severe Psoriasis

Ivanic, Mirjana G; Thatiparthi, Akshitha; Walia, Shikha; Liao, Wilson; Wu, Jashin J.

doi:10.36849/jdd.5845

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Specifically, in all oral systemic treatment cohorts, nearly 90% of patients were taking topical treatment during the 12‐month follow‐up period, and phototherapy frequency ranged from 0.22 to 0.25 PPPM among patients treated with PDE‐4 inhibitor and vitamin A. Combining oral systemic treatments with phototherapy or topical treatments has been observed to improve treatment outcomes in moderate‐to‐severe PsO, demonstrating consistent trends with those reported in the literature 8,37 . Comorbidities such as PsA and associated treatments have also been shown to increase HCRU and related costs 38 .…”

Section: Discussionsupporting

confidence: 65%

“…28,35 those reported in the literature. 8,37 Comorbidities such as PsA and associated treatments have also been shown to increase HCRU and related costs. 38 In our study, 5.4% of patients had a recorded PsA diagnosis during the 12-month follow-up period.…”

Section: Discussionmentioning

confidence: 99%

“…Combining oral systemic treatments with phototherapy or topical treatments has been observed to improve treatment outcomes in moderate‐to‐severe PsO, demonstrating consistent trends with those reported in the literature. 8 , 37 Comorbidities such as PsA and associated treatments have also been shown to increase HCRU and related costs. 38 In our study, 5.4% of patients had a recorded PsA diagnosis during the 12‐month follow‐up period.…”

Section: Discussionmentioning

confidence: 99%

“…1,4 Systemic therapies are often combined with phototherapy to attain better treatment efficacy. 7,8 A recent epidemiological survey by the Japanese Society for Psoriasis Research reported that between 2013 and 2018, in a population of patients with PsO, in 132 medical institutions, 9 approximately 68.9% of patients with PsO received topical treatments, 9.1% of patients received phototherapy, 26.6% of patients were treated with oral systemic drugs, and 18.6% of patients were treated with biologics. 9 Despite the wide variety of available treatments, the management of PsO has been associated with poor persistence and adherence worldwide.…”

Section: Introductionmentioning

confidence: 99%

“…Common biologics (and biosimilars) include tumor necrosis factor (TNF) inhibitors, such as adalimumab and infliximab; the interleukin (IL)‐12/23 inhibitor ustekinumab; IL‐23 inhibitors, such as guselkumab and risankizumab; and IL‐17 inhibitors, such as secukinumab, ixekizumab, and brodalumab 1,4 . Systemic therapies are often combined with phototherapy to attain better treatment efficacy 7,8 . A recent epidemiological survey by the Japanese Society for Psoriasis Research reported that between 2013 and 2018, in a population of patients with PsO, in 132 medical institutions, 9 approximately 68.9% of patients with PsO received topical treatments, 9.1% of patients received phototherapy, 26.6% of patients were treated with oral systemic drugs, and 18.6% of patients were treated with biologics 9 …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Treatment patterns, healthcare resource utilization, and costs in patients with moderate‐to‐severe psoriasis treated with systemic therapy in Japan: A retrospective claims database study

Tada

Kim

Spanopoulos

et al. 2022

The Journal of Dermatology

View full text Add to dashboard Cite

The real-world treatment landscape for patients with moderate-to-severe psoriasis receiving systemic therapies in Japan is not well understood. This study describes the demographic and clinical characteristics, treatment patterns, healthcare resource utilization, and psoriasisassociated costs in these patients. This retrospective observational study used data from the Japan Medical Data Center database between January 2016 and December 2020. Eligible patients had a confirmed diagnosis of psoriasis, ≥1 claim for a systemic treatment of interest, medical history for ≥6 months, and follow-up data for ≥12 months. Systemic therapies comprised biologics (tumor necrosis factor and interleukin inhibitors) and oral treatments (a phosphodiesterase-4 inhibitor, immunosuppressants, and vitamin A). Patient demographics and clinical characteristics, treatment patterns, healthcare resource utilization, and costs were evaluated. The study identified 1770 patients satisfying all inclusion criteria. The mean age was 49.0 years, with 68% of patients aged 20-54 years. Overall, 90.6% and 9.4% of patients received oral medications and biologics as index treatment, respectively. Treatment patterns, healthcare resource utilization, and costs were assessed for treatments received by ≥20 patients (n = 1730). During the 12-month follow-up period, 1102/1730 patients (63.7%) discontinued index treatment, of whom 9.9% switched to alternative systemic treatments.The persistence rate was ≥70% for most biologics and <50% for oral systemic treatments. All 1730 patients had ≥1 all-cause outpatient visit (2.0 visits per person per month) and hospitalization frequency was ≤0.01 per person per month. Persistent patients incurred inflationadjusted costs of Japanese Yen (JPY) 88 667 per person per month. Treatment switching was associated with an increase in total cost: JPY 128 039 per person per month after switching versus JPY 117 504 before switching. This study of Japanese patients with moderate-tosevere psoriasis demonstrated low persistence, high discontinuation, and low rates of treatment switching with systemic therapies. Switching was associated with increased total cost. These results indicate unmet needs for new treatments.

show abstract

Section: Discussionsupporting

confidence: 65%